Severe antibody-mediated human insulin resistance: Successful treatment with the insulin analog lispro: A case report

Diabetes Care

Volumn 20, Issue 1, 1997, Pages 71-73

  Lahtela, Jorma T ^a   Knip, Mikael ^b   Paul, Robert ^c   Antonen, Jaakko ^a   Salmi, Jorma ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b UNIVERSITY OF OULU   (Finland)

^c Oy Eli Lilly Finland Ab   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; INSULIN; INSULIN ANTIBODY; INSULIN DERIVATIVE; INSULIN LISPRO; ISOPHANE INSULIN; NEUTRAL INSULIN;

ADULT; ANTIGEN BINDING; ARTICLE; CASE REPORT; HUMAN; HYPOGLYCEMIA; IMMUNOGENICITY; INFUSION PUMP; INSULIN RESISTANCE; INSULIN TREATMENT; MALE;

EID: 0031022955     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.20.1.71     Document Type: Article

References (11)

1. van Haeften TW: Clinical significance of insulin antibodies in insulin-treated diabetic patients. Diabetes Care 12:641-648, 1989
2. Reeves WG: The immune response to insulin: characterisation and clinical consequences. In The Diabetes Annual/2. Alberti KGMM, Krall LP, Eds. Amsterdam, Elsevier, 1986, p. 81-93
3. Schernthaner G: Immunogenicity and allergic potential of animal and human insulins. Diabetes Care 16 (Suppl. 3):155-165, 1993
4. Brange J, Owen DR, Kang S, Volund A: Monomeric insulins and their experimental and clinical implications. Diabetes Care 13:923-954, 1990
5. Vähäsalo P: Autoantibodies to insulin have similar affinity to that of antibodies to exogenous insulin but lower binding capacity. Eur J Clin Invest 22:772-776, 1992
6. Fineberg SE, Galloway JA, Fineberg NS, Rathbun MJ, Hufferd S: Immunogenicity of recombinant DNA human insulin. Diabetologia 25:465-469, 1983
7. Sodoyez JC, Koch M, Sodoyez-Goffaux F: Anticorps anti-insuline: méthodologie et implications cliniques. Diabete Metab 17:255-269, 1991
8. Lassman-Vague V, Belicar P, Raccah D, Vialettes B, Sodoyez JC, Vague P: Immunogenicity of long-term tntraperitoneal insulin administration with implantable programmable pumps. Diabetes Care 18: 498-503, 1995
9. Shipp JC, Cunningham RW, Russel RO, Marble A: Insulin resistance: clinical features, natural course and effect of adrenal steroid treatment. Medicine 44:165-169, 1965
10. Ottesen JL, Nilsson P, Jami J, Weilguny D, Dührkop M, Bucchini D, Havelund S, Fogh JM: The potential immunogenity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia 37:1178-1185, 1994
11. Fineberg NS, Fineberg SE, Anderson JH, Birkett M, Gibson RG, Hufferd S: Does LysPro (B28,29) human insulin analog have altered immunogenicity in patients with type I diabetes? (Abstract). Diabetologia 37 (Suppl. 1):167, 1994